痴呆症患者的药物评价和临床结果:一个全面的综述
Rishabh Sharma1, Neil Mahajan2, Sarah Abu Fadaleh1
1School of Pharmacy, University of Waterloo, 10 Victoria St S A, Kitchener, ON N2G 1C5, Canada.
Pharmacy (Basel, Switzerland)
|October 27, 2023
概括
对老年痴呆症患者的药物评价显示出潜力,但缺乏对关键结果的广泛研究. 需要更多的研究来了解对痴呆症护理和患者幸福感的全部影响.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
背景情况:
- 患有痴呆症的老年人经常经历多药和不适当的药物使用.
- 定期的药物审查是缓解这些问题的潜在策略,但在这个人群中证据有限.
研究的目的:
- 进行范围审查,确定药物审查对老年痴呆症患者临床结果的影响的知识差距.
主要方法:
- 在2022年1月之前,对Ovid MEDLINE,Ovid EMBASE和Scopus数据库进行了全面的搜索.
- 包括来自最初8346篇文章的22篇出版物,分析了57个确定结果.
主要成果:
- 确定结果包括药物使用评估,与药物相关的干预措施,与药物相关的问题,与痴呆相关的行为症状,成本效益和住院.
- 在测量药物审查对药物管理能力,药物坚持,生活质量和死亡率的影响的研究中发现了关键知识差距.
结论:
- 虽然药物评价为痴呆症患者提供了潜在的好处,但目前的研究还没有充分探索它们对关键临床结果的影响.
- 需要进一步的研究,以确定药物审查在这个脆弱人群中的全面益处.
相关概念视频
Dementia
120
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
120
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Drug Therapy
47
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
47
Psychosis: Goals of Pharmacotherapy
145
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
145
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281


